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Reduction of urinary connective tissue growth factor by Losar-
tan in type 1 patients with diabetic nephropathy.
Background. Connective tissue growth factor (CTGF) is an
important profibrotic cytokine implicated in development of
diabetic glomerulosclerosis. Urinary CTGF is reported to be
significantly increased in patients with diabetic nephropathy.
The present study aimed to investigate the short- and long term
effects of angiotensin II receptor blockade by Losartan on uri-
nary CTGF levels in hypertensive type 1 diabetic patients with
diabetic nephropathy.
Methods. Seventy-one hypertensive type 1 diabetic patients
with diabetic nephropathy were included in the study. After
a washout period of 4 weeks, the patients received Losar-
tan 50 mg, 100 mg, and 150 mg once daily in treatment pe-
riods each lasting 2 months. Thereafter, patients were fol-
lowed prospectively during treatment with Losartan 100 mg
o.d. with a total mean follow-up time of 36 months. At base-
line, after 2, 4, and 6 months and then biannually, urinary
and plasma CTGF levels [enzyme linked immunosorbent assay
(ELISA) fibroGen], albuminuria (Turbidimetry), glomerular
filtration rate (GFR) [51-creatinine ethylenediaminetetraacetic
acid (51Cr-EDTA plasma clearance)] and 24 hours blood pres-
sure (TM2420)) were determined.
Results. Baseline levels of urinary and plasma CTGF were
7076 (5708 to 8770) ng/24 hours [geometric mean (95% CI)] and
12.7 (7.3) ng/mL [mean (SD)], respectively. Albuminuria, GFR,
and arterial blood pressure at baseline were 1152 (937 to 1416)
mg/24 hours, 88 (24) mL/min/1.73 m2, and 153/80 (17/9) mm
Hg, respectively. Losartan significantly reduced urinary CTGF
by 21% (9 to 31) (95% CI) initially (P < 0.05 vs. baseline),
with no further reduction after increasing dose. The sustained
reduction in urinary CTGF was 22% (12 to 32) (P < 0.05 vs.
baseline). Rate of decline in GFR during the study was 3.2 (−1.6
to 15.9) mL/min/year [median (range)]. Reduction in urinary
CTGF was correlated with a lower rate of decline in GFR (r =
0.23, P = 0.05). Plasma CTGF remained unchanged throughout
the study.
Key words: CTGF, diabetic nephropathy, angiotensin II receptor block-
ade.
Received for publication September 27, 2004
and in revised form November 8, 2004
Accepted for publication January 7, 2005
C© 2005 by the International Society of Nephrology
Conclusion. Our 3-year study demonstrates that Losartan
persistently reduces urinary CTGF excretion, which is associ-
ated with a slower rate of decline in GFR.
Diabetic nephropathy is characterized by expansion of
the extracellular matrix in the mesangium and thicken-
ing of glomerular and tubular structures [1]. Angiotensin
II plays a central role in the initiation and progression
of diabetic glomerulopathy, as a true cytokine that regu-
lates cell growth, inflammation and fibrosis, contributing
to progression of renal disease [2, 3]. Extracellullar ma-
trix accumulation has been attributed to hemodynamic
changes associated with mechanical stress or factors such
as angiotensin II and transforming growth factor-b (TGF-
b) [4]. Recent studies have suggested that connective
tissue growth factor (CTGF) could be a mediator of
the profibrogenic effects of angiotensin II in the kidney
[5]. Up-regulation of glomerular CTGF gene expression
has been demonstrated in studies of experimental di-
abetic glomerulopathy and human renal biopsies from
various renal diseases, including diabetic nephropathy
[6, 7]. CTGF regulation is primarily acting downstream
from TGF- b [5, 7], although recent studies have sug-
gested TGF-b–independent induction of CTGF by hy-
perglycemia [8].
Animal and human studies have indicated that renin-
angiotensin-aldosterone system (RAAS) blockade is
likely to reduce renal expression and urinary levels of
TGF-b in diabetic glomerulopathy [9–14]. Thus, block-
ade of the RAAS is likely to reduce glomerular scarring
in diabetic nephropathy. Profibrotic factors such as CTGF
and TGF-b may therefore represent supplementary ther-
apeutic targets in treatment of diabetic nephropathy. The
aim of the present study was to investigate the short- and
long-term effect of increasing doses of angiotensin II re-
ceptor blockade (ARB) by Losartan on urinary levels of
CTGF.
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METHODS
The present study was designed to investigate the long-
term renoprotective effects of Losartan in type 1 dia-
betic patients with diabetic nephropathy homozygous for
the angiotensin-converting enzyme/insertion (I) or dele-
tion (D) (ACE/ID) polymorphism, which have been pub-
lished previously [15]. Fourteen heterozygous patients
were followed by the same protocol since genotypes were
unknown at inclusion in part of the patients. Data from
the complete group of patients, including all ACE/ID
genotypes, have not been published previously.
All antihypertensive medication was withdrawn for
at least 4 weeks prior to enrollment. The patients re-
ceived Losartan 50 mg, 100 mg, and 150 mg once daily
in three treatment periods each lasting 2 months. There-
after, patients were followed prospectively during treat-
ment with Losartan 100 mg once daily with a total mean
follow-up time of 36 months. Additional antihyperten-
sive treatment (i.e., diuretics, calcium channel blockers,
and alpha blockers) were given in an attempt to achieve
a target blood pressure below 135/85 mm Hg. Dietary in-
take of protein and salt were not restricted. Blood pres-
sure measurements and adjustment of antihypertensive
medication were performed every third month. Clinical
investigations were carried out every 6 months and in-
cluded determination of urinary and plasma CTGF, albu-
minuria, glomerular filtration rate (GFR), 24-hour blood
pressure, and laboratory variables.
All patients fulfilled the compliance criteria of taking
more than 85% of the study medication.
All patients fulfilled the following inclusion criteria:
diabetic nephropathy, GFR >60 mL/min/1.73 m2, office
blood pressure >135/85 mm Hg, and age between 18
and 70 years. Diabetic nephropathy was diagnosed clini-
cally in patients with persistent albuminuria (>300 mg/24
hours), diabetic retinopathy, and absence of other evi-
dence of kidney or renal tract disease [16]. Patients were
excluded if they had a history of malignant hypertension,
congestive heart failure, myocardial infarction, or stroke
within the last 3 months. The study was performed ac-
cording to the principles of the Declaration of Helsinki
and approved by the Ethical Committee of Copenhagen
County. All patients gave their informed consent.
Urinary CTGF was determined as the geometric mean
of at least two consecutive 24-hour urine collections, com-
pleted immediately before each visit. Urinary and plasma
levels of CTGF were determined by means of a sand-
wich enzyme-linked immunosorbent assay (ELISA), us-
ing two distinct monoclonal antibodies against the CTGF
protein (FibroGen, Inc., South San Francisco, CA, USA).
This assay detects both CTGF N-terminal fragments as
well as the full-length CTGF protein. The sensitivity of
this assay was 0.1 ng/mL, interassay and intra-assay vari-
ations were 26% and 6%, respectively [17].
Table 1. Demographic characteristics of the patients
Gender male/female 25/46
Age years 44 (9)
Duration of diabetes years 32 (9)
Duration of nephropathy years 12 (5)
Retinopathy background/proliferative % 19/81
Mean (SD).
Albuminuria was determined as the geometric mean
of at least two consecutive 24-hour urine collections,
completed immediately before each visit (Turbidimetry)
(Cobas Mira Plus, Roche).
GFR was measured after a single intravenous injection
of 3.7 MBq 51-creatinine-ethylenediaminetetraacetic
acid (51Cr-EDTA) at 8:00 a.m. by determining the ra-
dioactivity in venous blood samples taken 180, 200, 220,
and 240 minutes after the injection [18, 19]. The results
were standardized for 1.73 m2 body surface area, using the
patient’s surface area at the start of the study. The mean
coefficient of variation in GFR of each patient from day
to day was 4%.
Blood pressure values are based on 24-hour ambula-
tory blood pressure measurements performed with the
Takeda TM2420, version 7 (A&D, Tokyo, Japan) device.
Blood pressures were measured every 15 minutes during
the day (7:00 a.m. to 11:00 p.m.) and every 30 minutes
during night (11:00 p.m. to 7:00 a.m.). Values were aver-
aged for each hour before calculating the 24-hour blood
pressure.
Urinary CTGF and albuminuria were logarithmically
transformed before statistical analysis owing to their
skewed distribution, and are given as the geometric
means (95% CI). Rate of decline in GFR is given as
median (range). Clinical characteristics of participants
(Table 1) are expressed as mean (SD), other data as
mean (SEM). Comparisons of normally or log normally
distributed parameters were performed with the use of
Student t test. Data are analyzed by analysis of variance
(ANOVA) according to a general linear model, repeated
measures method. The rate of decline in kidney function
was analyzed by regression lines for GFR over individ-
ually determined times during the treatment period. A
P value < 0.05 was considered significant (two-tailed).
Data were analyzed by SPSS, 11.5 (SPSS, Inc., Chicago,
IL, USA).
RESULTS
Baseline levels of urinary and plasma CTGF were 7076
(5708 to 8770) ng/24 hours [geometric mean (95% CI)]
and 12.7 (1) ng/mL [mean (SEM)], respectively. Losar-
tan significantly reduced urinary CTGF by 21% (9 to
31) (95% CI) initially (P < 0.05 vs. baseline), with no
further reduction after increasing dose. The sustained
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Fig. 1. Urinary connective tissue growth factor (CTGF) excretion in
hypertensive type 1 diabetic patients with diabetic nephropathy during
Losartan treatment. All P < 0.05 vs. baseline.
Table 2. Clinical data in hypertensive type 1 diabetic patients with
diabetic nephropathy during 36 months of treatment with Losartan
100 mg
Baseline 36 months
Glomerular filtration rate 87 (3) 77 (4)b
mL/min−1/1.73−1 m2
24-hour systolic blood 153 (2) 133 (2)b
pressure mm Hg
24-hour diastolic blood 80 (1) 71 (1)b
pressure mm Hg
Albuminuriaa mg/24 hours 1152 (937–1416) 271 (167–444)b
Hemoglobin A1c% 8.8 (0.2) 9.2 (0.2)
Serum cholesterol mmol/L 5.3 (0.1) 5.1 (0.1)
Mean (SE)
aGeometric mean (95% CI)
bP < 0.05 vs. baseline
reduction in urinary CTGF was 22% (12 to 32) (P < 0.05
vs. baseline) (Fig. 1). Plasma CTGF remained unchanged
throughout the study (Table 3).
Rate of decline in GFR during the study was 3.2 (−1.6
to 15.9) mL/min/year [median (range)]. Arterial blood
pressure during the follow-up period was 139/74 (2/1) mm
Hg.
Baseline levels of urinary CTGF and albuminuria were
correlated (r = 0.34, P < 0.01). Furthermore, correlation
between changes in urinary CTGF and albuminuria dur-
ing follow-up was also found (r = 0.54, P < 0.01) (Fig. 2A).
In addition, reduction in urinary CTGF correlated with a
lower rate of decline in GFR, as illustrated in Figure 2B
(r = 0.23, P = 0.05).
DISCUSSION
The present study prospectively investigated the effect
of ARB on urinary CTGF excretion in hypertensive type
1 diabetic patients with diabetic nephropathy. Urinary
CTGF excretion was significantly reduced during Losar-
tan treatment without additional effect by dose escalation
or long term treatment. Furthermore, urinary CTGF was
correlated to albuminuria and CTGF reduction associ-
ated with a slower rate of decline in GFR. These findings
may suggest that the renoprotective effect of Losartan in
part is due to lowering of CTGF metabolism.
Urinary excretion of CTGF has recently been investi-
gated in diabetic patients with and without nephropathy
[20, 21]. Riser et al [21] investigated in a preliminary study
the hypothesis of urinary CTGF being a potential early
predictor of diabetic nephropathy before development of
albuminuria. Seven patients (four requiring insulin) with
diabetic renal disease as evaluated by dipstick and/or el-
evated serum creatinine, and six patients (four requir-
ing insulin) with urinary protein excretion and serum
creatinine within normal range were investigated. Uri-
nary CTGF was markedly higher in most patients with
diabetic renal disease, but no significant differences be-
tween patients with and without ACE inhibition were
observed. However, number of patients was too small
to precisely evaluate this effect. The study also demon-
strated presence of low concentrations of urinary CTGF
in healthy volunteers as compared to sixfold higher levels
in diabetic patients with nephropathy. Further longitudi-
nal studies are required to investigate the concept that
urinary CTGF may be an early predictor in diabetic pa-
tients destined for diabetic nephropathy. Gilbert et al [20]
investigated in a cross-sectional study urinary CTGF ex-
cretion in 31 type 1 diabetic patients. Ten patients had
normal albumin excretion, eight were microalbuminuric,
five patients with overt nephropathy without ACE in-
hibition, and eight with overt nephropathy, but treated
with an ACE inhibitor. Urinary CTGF increased progres-
sively from normo-, to micro-, and macroalbuminuria. In
accordance with our study, urinary CTGF excretion in
macroalbuminuric patients with blockade of the RAAS
was significantly lower compared to patients who were
not. Furthermore, urinary CTGF was correlated to al-
buminuria which may suggest that the magnitude of uri-
nary CTGF excretion is related to the severity of kidney
disease.
Titration of renoprotective therapy upon achieving the
maximum antiproteinuric effect has attracted great at-
tention lately [22, 23]. We have previously demonstrated
that the optimal dose of Losartan for renoprotection
and blood pressure reduction in diabetic nephropathy
is 100 mg o.d. [22]. However, profibrotic factors such
as TGF-b and CTGF might be supplementary thera-
peutic targets and titration parameters in treatment of
diabetic and nondiabetic glomerulopathies. In a recent
dose-response study in proteinuric rats with nondiabetic
kidney disease and major overexpression of TGF-b , Pe-
ters, Border, and Noble [24] demonstrated an additional,
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Table 3. Plasma connective tissue growth factor (CTGF) during Losartan treatment in hypertensive type 1 diabetic patients with diabetic
nephropathy
Baseline 4 months 6 months 12 months 24 months 30 months 36 months
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Fig. 2. Scatterplots of (A) changes in al-
buminuria vs. changes in urinary connec-
tive tissue growth factor (CTGF) (r = 0.54,
P < 0.01) and (B) rate of decline in glomeru-
lar filtration rate (GFR) vs. changes in urinary
CTGF (r = 0.23, P = 0.05).
blood pressure–independent, reduction in TGF-b during
high dose therapy with Losartan and enalapril. This study
revealed a clear dissociation between the dose required
for maximum blood pressure reduction and the optimal
dose of ACE inhibition and ARBs for inhibition of TGF-
b . However, in the present study we found no indica-
tions of additional antifibrotic effects by increasing the
dose of Losartan above the optimal dose for renoprotec-
tion and blood pressure reduction. The investigated dose
range was modest and further reduction of urinary CTGF
by higher Losartan doses can not be excluded. How-
ever, the missing dose response may indicate presence of
other contributing factors in diabetic patients (e.g., high
glucose). Experimental studies have demonstrated that
stimulation of cultured mesangial cells by angiotensin II
and high glucose concentration are mediated by the same
protein kinase C pathway [25]. Consequently, dose re-
sponse of Losartan on urinary CTGF may be inhibited
by high glucose concentration. Dose response studies in
diabetic animal with RAAS blockade and CTGF are not
available.
The observed reduction of urinary CTGF by Losar-
tan may reflect a specific inhibition of CTGF expres-
sion since previous experimental studies have demon-
strated that CTGF synthesis is specifically stimulated by
angiotensin II and inhibited by ARB treatment [5]. We
found no associations between changes in arterial blood
pressure and urinary CTGF excretion. However, reduc-
tion of glomerular pressure through dilation of the ef-
ferent arteriole during blockade of the RAAS decrease
proteinuria [3] and may also contribute to the reduction
of urinary CTGF. The reduction in urinary CTGF excre-
tion can not be explained by changes in glycemic control
or plasma cholesterol since both variables remained un-
changed during the study.
ARB treatment is known to reduce urinary TGF-b lev-
els in diabetic renal disease [10, 12]. CTGF synthesis is
activated downstream from TGF-b [5, 7] but may also be
induced independent of TGF-b by hyperglycemia and ad-
vanced glycation end products [8, 26, 27]. Recent studies
suggest that CTGF may be the mediator of profibrogenic
effects of angiotensin II [5, 26]. Our study suggests an in-
teraction between blockade of angiotensin II and CTGF
synthesis which may be renoprotective; however, signal-
ing pathways and others pathophysiologic mechanisms
of CTGF in diabetic nephropathy need further investiga-
tion.
CTGF is located in numerous tissues and overex-
pressed in vascular damage and atherosclerotic lesions
[28]. Plasma CTGF was unaffected by ARB in the present
study, but CTGF in plasma may originate from a variety
of tissues rather than exclusively reflecting renal expres-
sion. Thus, plasma CTGF may not be a valid parameter
in the evaluation of renal CTGF expression.
CTGF might be a mediator of the profibrogenic effects
of angiotensin II via the angiotensin II type 1 (AT1) re-
ceptor [5]. Animal studies have suggested that CTGF is
responsible for deposition of fibronectin and collagen I in
glomeruli and tubuli [5, 29]. In the present study, urinary
CTGF excretion was reduced at first examination after 2
months without further changes during long-term treat-
ment; however, beneficial effects on renal structure may
be expanding during sustained treatment.
Fifty-four patients in the present study were homozy-
gous for the ACE/ID polymorphism (II = 26; DD = 28).
Our previous study demonstrated that hypertensive type
Andersen et al: Urinary CTGF and Losartan in diabetic nephropathy 2329
1 diabetic patients with diabetic nephropathy homozy-
gous for the ACE/ID polymorphism have similar reno-
protective effects by treatment with Losartan [15]. Fur-
thermore, heterozygous patients followed by the same
protocol demonstrated analogous beneficial effects on
kidney function and blood pressure.
CONCLUSION
The present study investigated the effect of ARB on
urinary CTGF excretion in hypertensive type 1 diabetic
patients with diabetic nephropathy. Our 3-year study
demonstrates that Losartan persistently reduces urinary
CTGF excretion, which is associated with a slower rate
of decline in GFR.
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